GlassScriptPhysician profile
Michael G Kogan
NPI 1730297789
$1,099.05
in general payments reported to CMS, 2019-2025
15 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37.81 · 2020: $430 · 2021: $141 · 2022: $132 · 2023: $65.91 · 2024: $173 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $358.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $348.50 | 2020-2021 | |
| Dynasplint Systems INC. | $132.16 | 2022 | |
| Stryker Corporation | $119.41 | 2024 | Hoffmann |
| Smith+Nephew, INC. | $102.83 | 2019-2021 | |
| Novo Nordisk INC | $100.33 | 2023-2025 | Rybelsus, Ozempic |
| Zimmer Biomet Holdings, INC. | $72.06 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $40.72 | 2020-2025 | Zilretta |
| Pacira Therapeutics, INC. | $31.17 | 2020 | |
| Currax Pharmaceuticals LLC | $28.33 | 2024 | Contrave, Onzetra Xsail |
| Orthofix Medical, INC. | $26.02 | 2025 | Physio-Stim |
| Vertex Pharmaceuticals Incorporated | $24.25 | 2025 | |
| Glaxosmithkline, LLC. | $21.40 | 2023 | Shingrix, Arexvy |
| Lilly USA, LLC | $21.16 | 2025 | Zepbound, Mounjaro |
| Horizon Therapeutics Plc | $17.89 | 2019 | |
| Fidia Pharma USA INC. | $12.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kogan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.